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REGULAR ARTICLE
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Key points
•GRK6 regulates the
hemostatic response
by limiting platelet
activation via throm-
bin and adenosine
59-diphosphate.
•GRK6 regulates the
hemostatic response
by reducing PAR1/4-
and P2Y12-dependent
signaling.
G protein–coupled receptors (GPCRs) mediate the majority of platelet activation in response
to agonists. However, questions remain regarding the mechanisms that provide negative
feedback toward activated GPCRs to limit platelet activation and thrombus formation. Here
we provide the ﬁrst evidence that GPCR kinase 6 (GRK6) serves this role in platelets, using
GRK62/2 mice generated by CRISPR-Cas9 genome editing to examine the consequences of
GRK6 knockout on GPCR-dependent signaling. Hemostatic thrombi formed in GRK62/2mice
are larger than in wild-type (WT) controls during the early stages of thrombus formation,
with a rapid increase in platelet accumulation at the site of injury. GRK62/2 platelets have
increased platelet activation, but in an agonist-selective manner. Responses to PAR4 agonist
or adenosine 59-diphosphate stimulation in GRK62/2 platelets are increased compared with
WT littermates, whereas the response to thromboxane A2 (TxA2) is normal. Underlying these
changes in GRK62/2 platelets is an increase in Ca21mobilization, Akt activation, and granule
secretion. Furthermore, deletion of GRK6 in human MEG-01 cells causes an increase in Ca21
response and PAR1 surface expression in response to thrombin. Finally, we show that
human platelet activation in response to thrombin causes an increase in binding of GRK6 to
PAR1, as well as an increase in the phosphorylation of PAR1. Deletion of GRK6 in MEG-01
cells causes a decrease in PAR1 phosphorylation. Taken together, these data show that GRK6
regulates the hemostatic response to injury through PAR- and P2Y12-mediated effects,
helping to limit the rate of platelet activation during thrombus growth and prevent
inappropriate platelet activation.
Introduction
Platelets play a critical role in hemostasis, thrombosis, and inflammation. Once platelets are recruited
to the damaged vessel wall, the primary drivers of platelet activation are thrombin, adenosine
59-diphosphate (ADP), thromboxane A2 (TxA2), and collagen. With the exception of collagen, each of
these agonists signals through G protein–coupled receptors (GPCRs). The G proteins that function as
mediators for these receptors are a, b, and g heterotrimers. GPCRs turn on G proteins by promoting the
exchange of GDP for GTP. Ga and Gbg subunits then dissociate and stimulate their respective
effectors. Signaling terminates when Ga hydrolyzes bound GTP back to GDP. Platelet activation can be
Submitted 20 May 2019; accepted 25 November 2019; published online 3 January
2020. DOI 10.1182/bloodadvances.2019000467.
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regulated at multiple places in its signaling network, including at
the levels of receptor activation, intracellular Ca21 elevation, RAP1
activation, and integrin outside-in signaling.1 These different levels
of regulatory events are essential to achieve optimal platelet signaling
so that platelet activation is neither inadequate (allowing rebleeding
to occur) nor overly exuberant (risking vascular occlusion). The first
signaling node to control platelet activation after exposure to agonists
is at the level of receptor stimulation. In nucleated cells, there are
a number of well-described mechanisms for limiting signaling
through GPCRs, including receptor phosphorylation, internalization,
and shedding. Among them, one of the key regulators of GPCRs is
the agonist-dependent phosphorylation by GPCR kinases (GRKs)
followed by internalization of receptors.2-4 This process is also known
as desensitization, and it attenuates the receptor response in the
presence of continuous stimulation of agonists.3 Here we have
asked whether GRKs are regulators of platelet activation and, if
so, whether they impact the hemostatic response to injury.
The GRK family consists of 7 members (GRK1 to GRK7) that are
divided into 3 subfamilies: (1) the rhodopsin kinases, or visual GRKs
(numbers 1 and 7); (2) the GRK2/3 family, originally termed
b-adrenergic receptor kinases 1 and 2; and (3) the GRK4 family,
comprising GRK4, -5, and -6. GRK2, -3, -5, and -6 are ubiquitously
expressed. Others show a more tissue-specific distribution.5 GRKs
share a relatively conserved kinase domain, an N-terminal Regulator
of G protein signaling (RGS) homology domain that is bracketed
by a short N-terminal a-helical domain, and a variable C-terminal
lipid-binding region.4,6 One of the major differences between RGS
proteins and GRKs is that the RGS homology domains of GRKs
have little or no GTPase activating protein activity, which is the
hallmark of classical RGS proteins. Instead, the ability of GRKs to
attenuate signaling is primarily due to receptor phosphorylation.4,7
GRKs play an important role in cardiovascular physiology and the
development of cardiac disease.8-11 Changes in GRK expression
have been linked to many cardiovascular pathologies, including
myocardial infarction, hypertension, and cardiac hypertrophy. A
previous report shows that GRK6-deficient mice develop an
autoimmune-like disease.12 We have been able to detect GRK2,
GRK5, and GRK6 protein expression in both human and mouse
platelets, which is consistent with platelet transcriptome13 and
proteomics data.14,15 Based on estimated copy number, GRK6
is the form most predominantly expressed in both human and
mouse platelets. In a transfected cell–based assay, GRK6 contrib-
utes to the desensitization of P2Y12.
16 Nothing is known about the
impact of GRK6 on platelet activation and its role in modulating the
hemostatic response to injury.
In the present study, we show that GRK6 functions as a negative
regulator of platelet activation in vitro and the hemostatic response
to injury in vivo. Mice lacking GRK6 show an increased rate of
platelet deposition during the initial stage of hemostatic thrombus
formation after injury. When studied ex vivo, their platelets show an
agonist-selective increase in responses to thrombin and ADP,
but not to TxA2 or collagen. Finally, the data show that there is
increased binding of GRK6 to PAR1 during platelet activation by
thrombin. Increased binding of GRK6 is associated with increased
phosphorylation of PAR1 during human platelet activation. Based
on these observations, we propose that GRK6 helps to establish
a stable and controlled hemostatic plug during the early stages of
thrombus formation, halting the loss of blood without occlusion of
the vessel.
Methods
Mice
The generation of GRK6 knockout mice using the CRISPR-Cas9
genome-editing system was performed as described by Henao-Mejia
et al.17 Briefly, zygotes from C57BL/6 mice were injected with Cas9
messenger RNA (100 ng/mL) and guide RNAs (gRNAs) (50 ng/mL).
Embryos were then transferred to pseudo-pregnant C57BL/6
female mice. The founder mice were each bred to the F1 generation
using C57BL/6 mice for further analysis. All mouse protocols and
procedures were approved by the Institutional Animal Care and Use
Committee of the University of Pennsylvania or Thomas Jefferson
University.
Vascular injury
Hemostatic thrombus formation was observed in the cremaster muscle
microcirculation of male mice aged 8 to 12 weeks as previously
described.18 Briefly, Alexa Fluor 568–labeled anti-CD41 antibody
F(ab)2 fragments, Alexa Fluor 647–labeled anti–P-selectin, and
Alexa-647 anti-fibrin antibodies were administered via a catheter in
the jugular vein. Arterioles 30 to 50 mm in diameter were studied.
Vascular injury was induced using a pulsed nitrogen dye laser fired
through the microscope objective. Thrombus formation was observed
for 3 minutes and analyzed.
Other methods
Material and antibodies, cell culture, platelet preparation, flow
cytometry, platelet aggregation, and coprecipitation experiments
are described in supplemental Methods.
Statistical analysis
Results are presented as mean6 standard error of the mean (SEM)
as shown in the figure legends. Data were analyzed using the
Student t test. P # .05 was considered statistically significant.
Results
We used CRISPR-Cas9 genome editing to generate GRK62/2
mice by designing gRNAs targeting intron 1 and exon 4 of
mouse GRK6 (Figure 1A). This introduced a premature stop
codon and also generated a 450-bp deletion between intron 1 and
exon 4 (supplemental Figure 1A). The GRK62/2 mice generated
by crossing between GRK61/2 mice were born in the expected
Mendelian inheritance ratios (supplemental Table 1). The GRK62/2
mice were slightly smaller than their GRK61/1 littermates, but
caught up by 8 to 9 weeks (supplemental Figure 1B). There
was ;10% decrease in platelet counts in GRK62/2 mice. Mean
platelet volume, red cell count, and leukocyte count were normal
(supplemental Table 2). Deletion of GRK6 did not affect GRK2 or
GKR5 protein expression in mouse brain (Figure 1Bi) or in platelets
(Figure 1Bii).
GRK62/2 mice display an increased initial rate of
platelet accumulation in response to injury
Platelet function was studied in vivo with a well-established model
that uses a laser to make penetrating injuries in cremaster muscle
arterioles as previously described.18,19 The thrombus architecture
that forms consists of a core of tightly packed, P-selectin–positive
platelets overlaid with a shell of loosely adherent P-selectin–negative
platelets. Anti-CD41 is used as a marker for platelet deposition.
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Anti–P-selectin, which is an a-granule exocytosis marker, is used to
distinguish the core from the shell. Fibrin is detected with a fibrin-
specific monoclonal antibody that does not recognize fibrinogen.18
Thrombin activity and fibrin deposition in this model are limited to
the core.20
Representative images of hemostatic plugs formed in wild-type (WT)
and GRK62/2 mice 1 minute after injury are shown in Figure 2Ai.
Platelets accumulate more rapidly at the site of injury in GRK62/2
mice than in WT controls (Figure 2Aii). Notably, the slope of platelet
accumulation during the early stage of thrombus formation was
increased by 2.5-fold in GRK62/2 mice relative to WT controls
(Figure 2B). Overall, total platelet accumulation was significantly
increased in GRK62/2 mice compared with WT controls (Figure 2Aiii).
There was no significant difference in total P-selectin accumulation
(Figure 2Aiv). GRK62/2 mice also had normal fibrin accumulation
(Figure 2C), indicating that thrombin generation at the site of injury
is unaltered in GRK62/2 mice.
GRK6 deficient platelets have increased platelet
activation ex vivo
To assess the functional consequences of GRK6 deletion on
platelet function, integrin activation and a-granule secretion were
compared in platelets fromGRK62/2 and GRK61/1 (WT) littermates
using flow cytometry with antibodies specific to activated aIIbb3 and
P-selectin.21 The assays were performed using highly diluted platelet
suspensions to minimize signaling induced by secreted mediators
such as ADP and TxA2. The results in Figure 3A show that
platelet activation with the PAR4 thrombin receptor agonist
peptide (PAR4-AP), AYPGKF, had a pronounced leftward shift
in the dose/response curves for both integrin activation and P-selectin
exposure in the absence of GRK6, but no change in the maximal
response. There was also an increase in integrin activation when
GRK62/2 platelets were stimulated with ADP, but no increase in
P-selectin exposure in response to ADP under these conditions.
In addition, there was no increase in either integrin activation or
P-selectin exposure in response to the TxA2 analog, U46619, or
to convulxin, which is a ligand for the platelet collagen receptor,
glycoprotein VI. Platelet aggregation studies (Figure 3B) also
showed an increased response to AYPGKF and ADP in GRK62/2
platelets, but no increase in the response to U46619 or convulxin
(Figure 3B; supplemental Figure 6).
Deletion of GRK6 in mice enhances GPCR-dependent
signaling in platelets
To assess the functional consequences of GRK6 deletion on dense
granule secretion, we measured ATP release in platelets from WT
and GRK62/2 littermates. ATP and ADP in platelet-dense granules
are present in approximately the same equimolar concentrations.22
Single endpoint luminescence assays were used to quantify agonist-
induced platelet ATP release.23 There was a similar left shift in the
PAR4–AP-mediated dose response for ATP release, but no change
in the maximal release (Figure 4A). However, there was no difference
in ATP release between WT and GRK62/2 platelets in response
to convulxin, indicating that dense granule contents are normal in
GRK62/2 platelets (Figure 4B).
Agonists of which receptors are coupled to Gq cause activation of
phospholipase C-b leading to the hydrolysis of phosphotidylinositol-
4,5-bisphosphate and the production of diacylglycerol and inositol-
1,4,5-trisphosphate. The subsequent increase in [Ca21]i is due to
the release of Ca21 from intracellular stores followed by the
influx of Ca21 from the plasma membrane, known as store-
operated calcium entry. To determine whether deletion of GRK6
affects phospholipase C-b activation and subsequent Ca21
mobilization, we measured changes in Ca21 in response to each
of the GPCR agonists, with either the fluorescent Ca21 indicator
fura-2 AM, a ratiometric calcium indicator to measure intracellular
Ca21 concentrations, or fluo-4 AM, a nonratiometric Ca21 indicator
to measure influx and efflux that serves in this context to confirm
mouse
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Figure 1. Generation and characterization of GRK62/2
mice. (A) Strategy for introducing stop codon in the mouse
GRK6 gene. The gRNA 59 and gRNA 39 were combined
with Cas9 messenger RNA for subsequent cytoplasmic
injection of fertilized mouse eggs. Embryos were then trans-
ferred to pseudopregnant C57BL/6 female mice. After birth,
10-day-old mice were tail-snipped, and genomic DNA was
extracted for genotyping and sequencing. The founder mice
were each bred to the F1 generation using C57BL/6 mice
for further analysis. CRISPR-mediated genome editing in-
troduced a premature stop codon in exon 2. (B) Deletion of
GRK6 does not affect GRK2 or GRK5 protein expression in
mouse brain (i; N 5 3) or platelets (ii; N 5 2). Lysates were
probed for GRK6 before being successively reprobed for
GRK5, GRK2, or actin.
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fura-2 AM data. Consistent results were obtained from both assays
(Figure 4C-D; supplemental Figure 2). Similar to what we observed
in flow cytometric analysis and aggregation assays, PAR4-AP–induced
Ca21 flux showed a higher response in GRK62/2 mice than in WT
mice, but the same was not observed for U46619 and convulxin
(Figure 4D). In contrast, there was no difference in the Ca21
response to ADP. Note that Ca21 mobilization in response to ADP
is a readout for P2Y1- and not for P2Y12-mediated signaling. These
results suggest that GRK6 targets PAR4, but not P2Y1, thromboxane
receptors, or glycoprotein VI in mouse platelets.
ADP P2Y12 receptors are responsible for the Gi-mediated activa-
tion of the serine/threonine kinases, Akt1 and Akt2.24,25 Figure 5A
compares ADP-induced Akt activation inWT and GRK62/2 platelets
in the presence or absence of cangrelor (a P2Y12 antagonist) or
MRS2500 (a P2Y1 antagonist), using Ser473 phosphorylation of Akt
as a marker. Resting platelets exhibited negligible Akt phosphoryla-
tion whether or not GRK6 was present, but adding ADP caused
an increase in Akt phosphorylation that was greater in GRK62/2
platelets than WT controls (Figure 5Aii). Phosphorylation was
blocked by cangrelor, but not MRS2500 (Figure 5Aiii), indicating
that in both genotypes it was mediated by P2Y12, but not P2Y1.
Deletion of GRK6 does not affect PGI2-mediated
inhibitory signaling pathway in platelets
Endothelium-derived prostacyclin (PGI2) prevents premature plate-
let activation and accumulation, and the signaling pathways of PGI2
result in an increase in cyclic adenosine monophosphate (cAMP).
It has been suggested that the prostacyclin receptor (IP) is desensitized
in platelets.26We therefore examined the effects of theGRK6 knockout
on cAMP levels in resting platelets and in platelets stimulated with
PGI2. Our data show that basal levels were normal in GRK6
2/2
platelets, and there was no difference in PGI2-stimulated cAMP
formation in WT vs GRK62/2 platelets (Figure 5B), suggesting that
GRK6 is not involved in the inhibitory signaling pathway, which is
mediated by endothelial PGI2.
Deletion of GRK6 increases Ca21 response in
MEG-01 cells
Megakaryoblastic cells, MEG-01, express thrombin receptor PAR1
and PAR4 and have been used as a model to study the signaling of
megakaryocytes and platelets.27 In order to understand the function
of GRK6 in human megakaryocytes, we generated GRK6 knock-out
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Figure 2. Increased platelet accumulation in response to hemostatic injury. (A) Representative images of hemostatic plugs formed in WT and GRK62/2 mice 1 minute
after injury (Ai). (Aii) Confocal intravital fluorescence microscopy was performed to follow platelet accumulation and P-selectin expression. Data are mean 6 SEM; 46 injuries in
5 WT mice and 42 injuries in 5 GRK62/2 mice. (Aiii) Graph shows the area under CD41 vs time curve (area under the curve [AUC]). (Aiv) Graph shows the area under
P-selectin (1) vs time curve (AUC). The line and error bars show the median and interquartile range. (B) CD411 area at 45 seconds after injury (Bi). (Bii) The rate of CD41
deposition at 45 seconds after injury, and the bar graph represents the average slope of the liner trend line equation of each injury. Forty-one injuries in 5 WT mice and 41
injuries in 5 GRK62/2 mice. (C) Fibrin deposition after making small penetrating injuries in the cremaster muscle arterioles with laser in GRK62/2 mice and littermate controls.
Data are mean 6 SEM; 24 injuries in 5 WT mice and 25 injuries in 5 GRK62/2 mice (Ci). (Cii) Bar graphs represent the fibrin accumulation at the end of the 3-minute
observation period.
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MEG-01 cell clones using CRISPR-Cas9 techniques with 2 gRNAs
targeting at human GRK6 exon 3. Deletion of GRK6 in MEG-01
cells did not affect GRK2 or GRK5 protein expression (supplemental
Figure 4; Figure 7Ciii). Deletion of GRK6 did not affect PAR1 protein
expression (supplemental Figure 4B). Agonist-induced Ca21 release
was compared betweenWT and GRK62/2MEG-01 using fluo-4 AM.
Thrombin and the PAR1-AP, SFLLRN, evoked a rapid and significant
increase in Ca21 response in GRK62/2MEG-01 relative toWT cells.
However, there was no difference in Ca21 response in PAR4-AP
stimulated cells (Figure 6A). This indicates that GRK6 is involved in
human PAR1 receptor signaling but not in human PAR4 receptor
signaling. Consistent with the observation in mouse platelets, there
was no difference in U46619- or collagen-induced calcium
response between WT control and GRK62/2. ADP did not
cause any response in both WT and GRK62/2 cells (supple-
mental Figure 3). To investigate the impact of GRK6 deletion on
PAR1 surface expression, we used an anti-PAR1 antibody, ATAP2,
which recognizes cleaved as well as intact PAR1 receptors.28
Antibody binding to the platelet surface receptors was detected by
flow cytometry. Under normal culture conditions, PAR1 expression
on the surface of GRK62/2MEG-01 cells was increased compared
with WT cells. Stimulation with thrombin caused a decrease in
PAR1 surface expression in both WT and GRK62/2 MEG-01
cells (Figure 6Bi), but this decrease was more pronounced in WT
MEG-01 cells than in GRK62/2 MEG-01 cells (Figure 6Bii).
GRK6 forms a complex with PAR1 during
platelet activation
It has been reported in nucleated cells that GRKs only transiently
interact with GPCRs, and GPCR/GRK interactions are much
weaker compared with GPCR/G protein and GPCR/arrestin
interactions.29,30 To assess the interaction between GRK6 and
PAR1 during platelet activation, resting or activated platelets
lysates were subjected to immunoprecipitation. The results show
that there is little or no association of GRK6 with PAR1 in resting
platelets. Activation of platelets with thrombin caused an increase
in binding of GRK6 to PAR1 (Figure 7A). Thus, these results
suggest that GRK6 and PAR1 interact directly during platelet
activation.
To investigate whether increased binding of GRK6 to PAR1 triggers
the phosphorylation of receptors, resting or activated human platelet
lysates were immunoprecipitated with an anti-PAR1 antibody
and blotted for phosphoserine. Results showed that the level of
Flow
0 100 200 300
0
1000
2000
3000
4000
5000
*
*
ns
GRK6-/-
WT
PAR4-AP(M)
Jo
n/
A(
M
FI
)
0 2 4 6 8 10
0
500
1000
1500
Jo
n/
A(
M
FI
) GRK6-/-
WT
ns ns
ns ns
U46619(M)
0 5 10 15 20
0
200
400
600
800
1000
ns
ns
*
*GRK6-/-
WT
Jo
n/
A(
M
FI
)
ADP(M)
GRK6-/-
WT
0 20 40 60 80 100
0
1000
2000
3000
4000
Jo
n/
A(
M
FI
)
ns
ns
Convulxin(ng/ml)
GRK6-/-
WT
0 20 40 60 80 100
0
500
1000
1500
2000
Convulxin(ng/ml)
ns
ns
P-
se
lec
tin
 e
xp
os
ur
e(
M
FI
)
P-
se
lec
tin
 e
xp
os
ur
e(
M
FI
)
GRK6-/-
WT
0 5 10 15 20
0
100
200
300
400
nsns
ns
ns
ADP(M)
P-
se
lec
tin
 e
xp
os
ur
e(
M
FI
)
0 2 4 6 8 10
0
100
200
300
400
ns ns ns
ns
GRK6-/-
WT
U46619(M)
0 100 200 300
0
2000
4000
6000
*
*
ns
P-
se
lec
tin
 e
xp
os
ur
e(
M
FI
)
GRK6-/-
WT
PAR4-AP(M)
A
PAR4-AP(50M)
200 400 600-20
0
20
40
60
80
100
GRK6-/-
WT
Time(s)
Lig
ht
 tr
an
sm
isi
on
(%
)
PAR4-AP(75M)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
200 400 600-20
0
20
40
60
80
100
Time(s)
PAR4-AP(100M)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
200 400 600-20
0
20
40
60
80
100
Time(s)
U46619 (0.5M)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
200 400 600 800-20
0
20
40
60
80
100
Time(s)
U46619 (2M)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
200 400 600 800-20
0
20
40
60
80
100
Time(s)
U46619 (5M)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
200 400 600 800-20
0
20
40
60
80
100
Time(s)
ADP (5M)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
200 400 600 800-20
0
20
40
60
80
100
Time(s)
ADP (10M)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
200 400 600 800-20
0
20
40
60
80
100
Time(s)
ADP (20M)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
200 400 600 800-20
0
20
40
60
80
100
Time(s)
convulxin (75ng/ml)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
100 200 300 400-20
0
20
40
60
80
100
Time(s)
convulxin (100ng/ml)
GRK6-/-
WT
Lig
ht
 tr
an
sm
isi
on
(%
)
100 200 300 400-20
0
20
40
60
80
100
Time(s)
Aggregation
B
Figure 3. Increased integrin activation, a-granule exocytosis, and aggregation in platelets from GRK62/2 mice. (A) Platelets from GRK62/2 and littermate control
mice (WT) were stained with fluorophore-conjugated antibodies to either activated aIIbb3 (Jon/A antibody) or P-selectin and measured by flow cytometry. Platelets were
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PAR1 phosphorylation was increased upon thrombin stimulation
(Figure 7Bi). Similarly, we detected low levels of PAR1 in immuno-
precipitate fractions using antiphosphoserine antibodies in lysates
of resting platelets. However, PAR1 was highly enriched in
phosphoserine immunoprecipitate fractions following platelet
activation (Figure 7Bii), further supporting increased PAR1 serine
phosphorylation in response to thrombin activation in platelets. To
investigate further the role of GRK6 in the phosphorylation of PAR1,
we examined the level of PAR1 phosphorylation in both WT and in
GRK62/2 MEG-01 cells. Deletion of GRK6 in MEG-01 cells caused
a significant decrease in PAR1 phosphorylation in unstimulated cells
(Figure 7Ci-Cii). The remaining phosphorylation of PAR1 in GRK62/2
MEG-01 cells might be due to GRK2 or GRK5 expressed in the
cells (supplemental Figure 4Aii-iii). Collectively, these observations
suggest that GRK6 is involved in PAR1 phosphorylation during
platelet activation.
Discussion
Although initial adhesion of platelets to the vessel wall is driven by
collagen, the subsequent recruitment of additional platelets into
a growing thrombus requires mediators such as thrombin, TxA2, and
ADP, all of which act through GPCRs.31,32 Recently, a model of
the hemostatic response has been established in which the
development of gradients of platelet-soluble agonists presents
within the evolving platelet plug, resulting in a gradient of platelet
activation emanating from the injury site.18,19,33-35 In the core region
of the thrombus, thrombin mediates platelet activation with minimal
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requirement of ADP and TxA2. In contrast, ADP and TxA2 signal-
ing are critical for outer shell region formation. It has been long
recognized that during platelet activation, GPCRs undergo de-
sensitization following activation. For example, (1) PAR1 undergoes
rapid desensitization due to internalization, whereas activation-
dependent internalization of PAR4 is much slower than that seen
for PAR1.28,36-38 However, whether PAR1 or PAR4 receptor desen-
sitization is regulated by GRKs in platelets remains undetermined.
(2) Platelets also become desensitized to activation upon continued
exposure to ADP. Hardy et al show, using a transfected cells–based
assay, that P2Y12 receptors undergo functional desensitization,
and that GRK2 and GRK6 are involved.16,39 However, whether
this mode of regulation exists in anucleate platelets is unclear.
Furthermore, the function of GRKs during hemostasis and thrombosis
is unknown.
In this study we asked whether platelet activation is regulated at the
receptor level to limit GPCR signaling. The results show that such
a rate-limiting mechanism is present in platelets involving GRK6.
GRK6 functions as a primary checkpoint to limit the intensity and
duration of signaling via particular GPCRs during platelet activation.
Deleting GRK6 in mouse platelets increases platelet reactivity in
a PAR4- and P2Y12-dependent manner. Total platelet accumulation
is also increased in GRK62/2 mice, which is primarily due to an
accelerated rate of early-phase platelet accumulation. Next, we
investigated the signaling mechanisms that might underlie the
observed phenotypic change. We demonstrate that cytosolic Ca21
release and a-granule secretion are increased when platelets
are activated with PAR4-AP. Akt activation is also increased in
GRK62/2 platelets in response to ADP stimulation. Collectively,
our observations show for the first time that deletion of GRK6
produces a pathway-selective gain of function in platelets (supplemental
Figure 5). The gain of function is confined to both PAR4-mediated
signaling, leading to elevated Ca21 mobilization and ATP release,
and P2Y12-mediated signaling, resulting in increased phosphorylation
of Akt.
Mouse platelets express PAR3 and PAR4. PAR4 is the principal
thrombin receptor in mouse platelets. Thrombin signaling in mouse
platelets is mediated by PAR3-faciliated cleavage of PAR4. As
noted previously, thrombin is generated close to the site of injury
and can induce maximal platelet activation independent of TxA2 and
P2Y12 signaling.
18,35 This is consistent with our observation that the
initial hemostatic plug forms much faster in GRK62/2 mice than in
WT control, with an increase in the rate of the platelet accumulation.
Furthermore, the increased size of the core region is driven by the
gradient of thrombin concentration emanating from the site of the
injury. Consistent with the leftward shift in the dose/response curve
of GRK62/2 platelets to the PAR4 agonist stimulation that we
observed, thrombin-driven platelet activation and corresponding
deposition in GRK62/2 mice continue to occur further out from the
injury site, where the thrombin concentration is too low to trigger
a response in WT platelets. During plug extension, additional
platelet recruitment in the outer shell region requires ADP and TxA2.
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Figure 5. The impact of deleting GRK6 on Akt phosphorylation. (A) Gel-filtered platelets from GRK62/2 mice or matched WT controls were lysed directly or incubated
with 10 mM ADP for 5 minutes in the presence or absence of the P2Y1 antagonist MRS2500 (50 mM) or the P2Y12 antagonist cangrelor (100 nM), as indicated. (Ai) Lysates
were probed with anti–p-Akt (S473) and reprobed with anti-Akt antibody. (Aii) The p-Akt signal was normalized to the Akt loading control and is represented as signal relative
to that of the WT without antagonist and (Aiii) relative to that of the WT under the same conditions in the presence of the P2Y1 antagonist MRS2500. Data are mean 6 SEM
(N 5 3). (B). There is no difference of cAMP formation in WT vs GRK62/2. (Left) Basal cAMP concentration in GRK62/2 platelets (N 5 4) and matched controls (N 5 4).
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In this study, among the agonists tested, PAR4 peptide produced
the greatest responses in flow, a-granule exocytosis, and Ca21
mobilization assays. ADP stimulation also generated a signifi-
cant increase in integrin activation, platelet aggregation, and
P2Y12-mediated Akt activation, but had no effect on Ca
21
mobilization, which is P2Y1 mediated. Notably, knocking out
GRK6 does not affect TxA2-mediated signaling. TxA2 signals
through the thromboxane receptor (TP) receptor, and the TP
receptor is encoded by a single gene that can be alternatively
spliced in the carboxyl-terminal tail leading to 2 variants, TPa
(343 residues) and TPb (407 residues), that share the first 328
amino acids. In nucleated cells, it has been shown that the TPb,
but not the TPa, undergoes agonist-induced internalization.40
TxA2-stimulated effects in platelets are mediated predominantly
through the a isoform.41 Because GRK6 mainly phosphorylates
the C-terminus of GPCRs, we propose that GRK6 cannot
phosphorylate TPa and thus does not regulate platelet TxA2
signaling because TPa has shorter C-terminus. In addition, our
data also suggest that GRK6 is not involved in the inhibitory
signaling pathway mediated by endothelial PGI2.
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Figure 6. The impact of deleting GRK6 on Ca21 release in MEG-01 cells. (A) MEG-01 cells were loaded with fluo-4 AM, and the cells were stimulated with thrombin
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In human platelets, thrombin signals through 2 GPCRs, PAR1 and
PAR4. In contrast to mouse PAR4 and PAR3, human PAR1 and
PAR4 have functional differences that are complementary, and both
are essential for platelet activation, although at a different scale and
with different signaling kinetics.42,43 Our current studies in human
MEG-01 cells show that there is an increase in Ca21 response to
PAR1 agonist when GRK6 is absent, but no change in Ca21
response to PAR4 agonist. Why is there an effect on mouse
PAR4 but not human PAR4? First, human PAR4 has been shown
to internalize much less robustly than PAR1, likely because
human PAR4 has fewer Ser/Thr phosphorylation sites than human
PAR1.37 Furthermore, the C-terminus of human PAR4 has fewer
Ser/Thr phosphorylation sites compared with mouse PAR4. Thus, it
would be interesting to compare putative GRK6-mediated phos-
phorylation sites in human PAR4 vs mouse PAR4 in a future study.
The deletion of GRK6 does not affect TxA2-induced Ca
21 response,
which mimics what we have seen in GRK62/2 mouse platelets.
MEG-01 cells normally do not respond well to weaker agonists,
such as collagen and ADP,44 and as such we cannot at this point
compare the response of MEG-01 cells to these agonists with what
we have seen in mouse platelets. Finally, the results from our current
study show that platelet activation by thrombin causes increased
association between GRK6 and PAR1, indicating that GRK6 is
involved in PAR1-mediated signaling in platelets. Consistent with
increased GRK6 binding to PAR1, there is an increase in serine
phosphorylation of PAR1 in human platelets in response to thrombin
stimulation. Along with this, we observed a decrease in PAR1
internalization in MEG-01 cells lacking GRK6, and deletion of GRK6
in MEG-01 cells caused a decrease in serine phosphorylation of
PAR1. Collectively, this places GRK6 at a checkpoint at the
receptor level that balances the need for platelets to respond quickly
in response to vascular injury while retaining its function as amolecular
brake acting on PAR signaling, limiting platelet activity.
Along with GRK6, there are several other members of the GRK
family expressed in platelets.14-16 The gain-of-function phenotype in
GRK62/2mice suggests that GRK6, GRK5, and GRK2 may not be
fully redundant. This conclusion awaits studies on platelets lacking
GRK5 or GRK2. Finally, in nucleated cells, GRKs are generally
considered to regulate receptor desensitization via their canonical
role (GRK-mediated GPCR phosphorylation), and GRKs-mediated
GPCR desensitization can occur rapidly in some cell types.
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However, GRK2 and GRK5 can also mediate GPCR signaling
through noncanonical actions (kinase-independent molecular
interactions). Interestingly, GRK62/2 mice show an increased
rate of initial platelet accumulation in vivo in response to injury,
suggesting that the effect of GRK6 deletion is primarily on the
early stages of platelet activation. GPCR desensitization in platelets,
a process that may serve as a protective mechanism to prevent
excessive platelet accumulation, has generally been thought of as
a late signaling event in platelets. However, this statement has not
been experimentally validated in vivo. Interestingly, desensitization
of epinephrine-initiated human platelet aggregation occurs rapidly,
with a t1/2 of 3 minutes for desensitization.
45 Our studies show that
the maximum difference between platelet accumulation in GRK62/2
andWTmice is most prominent at early time points. This indicates that
GRK6-mediated GPCR desensitization actually occurs as an early
signaling event during platelet activation. Characterizing the under-
lying mechanism by which GRK6 regulates the receptor-level
signaling node, via either canonical (kinase-dependent mechanism)
or noncanonical actions (kinase-independent mechanism) during
platelet activation, is worthy to investigate in a future study.
In summary, the present studies demonstrate that platelet activation
downstream of GPCR-mediated signaling is limited by GRK6 at
the level of receptors. This leads us to suggest that the existence
of regulatory mechanism at the receptor level allows for tight regu-
lation of platelet activation even at its earliest stages. Combined with
what is known about the function of RGS proteins in platelets, further
investigating how GPCR and G protein signaling can be regulated
during platelet activation would provide a fruitful avenue for
understanding the hemostatic response to vascular injuries.
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